Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients
Top Cited Papers
Open Access
- 22 September 2011
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 118 (12), 3273-3279
- https://doi.org/10.1182/blood-2011-01-329508
Abstract
Thirteen patients with acute myeloid leukemia, 5 with active disease, 2 in molecular relapse, and 6 in morphologic complete remission (CR; median age, 62 years; range, 53-73 years) received highly purified CD56+CD3− natural killer (NK) cells from haploidentical killer immunoglobulin-like receptor–ligand mismatched donors after fludarabine/cyclophosphamide immunosuppressive chemotherapy, followed by IL-2. The median number of infused NK cells was 2.74 × 106/Kg. T cells were < 105/Kg. No NK cell–related toxicity, including GVHD, was observed. One of the 5 patients with active disease achieved transient CR, whereas 4 of 5 patients had no clinical benefit. Both patients in molecular relapse achieved CR that lasted for 9 and 4 months, respectively. Three of 6 patients in CR are disease free after 34, 32, and 18 months. After infusion, donor NK cells were found in the peripheral blood of all evaluable patients (peak value on day 10). They were also detected in BM in some cases. Donor-versus-recipient alloreactive NK cells were shown in vivo by the detection of donor-derived NK clones that killed recipient's targets. Adoptively transferred NK cells were alloreactive against recipient's cells, including leukemia. In conclusion, infusion of purified NK cells is feasible in elderly patients with high-risk acute myeloid leukemia. This trial was registered at www.clinicaltrial.gov as NCT00799799.Keywords
This publication has 18 references indexed in Scilit:
- Current perspectives of natural killer cell education by MHC class I moleculesNature Reviews Immunology, 2010
- Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificityBlood, 2009
- KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemiaLeukemia, 2009
- NK cells and cancer immunosurveillanceOncogene, 2008
- Human NK cells: from HLA class I‐specific killer Ig‐like receptors to the therapy of acute leukemiasImmunological Reviews, 2008
- Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value.Blood, 2007
- Human natural killer cell development and biologyBlood Reviews, 2005
- Killer immunoglobulin-like receptorsCurrent Opinion in Immunology, 2004
- Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic TransplantsScience, 2002
- Acute Myeloid LeukemiaNew England Journal of Medicine, 1999